Global Anti-Obesity Drugs Market is expected to reach US$ XX Mn by 2026 from US$ XX Mn in 2019, at a CAGR of 15.1% during the forecast period.

Global Anti-Obesity Drugs Market Overview:

Anti-obesity drugs are medications, which are used to reduce body weight by lowering cholesterol levels in the body. These drugs affect the human body's basic functions by modifying appetite or eating calories.
Global Anti-Obesity Drugs Market Dynamics:

The rising prevalence of obesity worldwide is the major factor driving the market growth.

The anti-obesity drugs market is expected to rise due to the rising cases of obesity and overweight among patients worldwide as a result of inactive lifestyles and bad eating habits. The World Health Organization (WHO) estimates that over 1.8 billion adults aged 18 and above were overweight in 2016.

The leading players in the industry are also undergoing product creation and finding market approvals as a result of the rise in the global obesity population. In 2018, Novo Nordisk formed an alliance with Evotec AG to discover and produce drug molecules to treat a variety of metabolic disorders, such as obesity, diabetes, and other related illnesses. The increasing need for medicines that have long-term effects is expected to create enormous opportunities for market vendors to develop new products. This factor is expected to eventually aid the market growth.

The rising prevalence of obesity, as well as type II diabetes, has prompted many market analysts and vendors to conduct studies on drugs that can treat both obesity and type II diabetes. MED10382 by AstraZeneca and Bimagrumab by Novartis are two of the medicines being tested for obesity and type II diabetes.

However, drug side effects and the lack of combination therapy are expected to limit the market's growth. Along with this, the market for anti-obesity drugs is expected to be hampered by the rising acceptance of alternative alternatives such as gyms, exercise spas, treatments to minimise obesity, patient compliance for surgical procedures, and a high change in diet plan. Furthermore, the launch of new anti-obesity drugs, as well as untapped opportunities in emerging markets, would boost demand growth over the forecast period.

The report has profiled fifteen key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.
Global Anti-Obesity Drugs Market Segment Analysis:

The Global Anti-Obesity Drugs Market is segmented on the basis of Mechanism of Action, Drug Type and Distribution Channel.

Based on Drug Type, the Prescription Drugs segment is expected to hold the dominant market share during the forecast period. The easy availability of therapeutically effective anti-obesity drugs in the market is credited with the segment's rapid growth. The increasing consumption of junk food is causing global population health to deteriorate, leading to an increase in the prevalence of obesity, especially in developing countries.

Various companies have been exploring novel medicines that help people lose weight and manage diabetes as a potential in battling COVID-19, which has serious effects on the obese population. Novo Nordisk AS revealed in September 2020 that it is conducting research in COVID-19 patients on the GLP-1 medication used to treat obesity. Such research activities contribute to the rise in demand for Prescription.



To know about the Research Methodology :- Request Free Sample Report
Global Anti-Obesity Drugs Market Regional Insights:

North America is expected to account for the largest market share during the forecast period.

North America is expected to hold a dominant market share during the forecast period, owing to the increase in the obese population and high healthcare expenditure are the primary factors driving the market's growth. The Centres for Disease Control and Prevention (CDC) states that adult obesity prevalence is growing owing to current circumstances of work from home, less physical activity, and financial and other stress among the adult population which contributes to the market growth in the region.

The Asia Pacific is expected to witness the highest growth during the forecast period.

The factors contributing to the market growth in the region are the rising consumer disposable income, rise in healthcare expenses, and the increasing prevalence of obesity and both type I and type II diabetes. Also, the increasing demand for drugs and rising awareness about anti-obesity drugs in Asia Pacific countries such as India, China and South Korea will also contribute to the region's anti-obesity drugs market growth.

The report also helps in understanding the Global Anti-Obesity Drugs Market dynamics, structure by analyzing the market segments and project the Global Anti-Obesity Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anti-Obesity Drugs Market make the report investor’s guide.
Global Anti-Obesity Drugs Market, Key Developments:

• In January 2021, Novo Nordisk AS announced a collaboration with the start-up Fauna Bio to study the molecules and pathways that control metabolism in hibernating animals in order to find new therapeutic approaches to obesity.

• Saxenda, Novo Nordisk's anti-obesity drug, was approved by the US Food and Drug Administration (FDA) in December 2020 for the treatment of obesity in adolescents aged 12 to 17.

• Eisai Inc. reported in February 2019 that the United States Food and Drug Administration (FDA) had approved its latest supplementary drug application. BELVIQ, the company's anti-obesity drug, will have its labeling updated as a result of this.
Global Anti-Obesity Drugs Market Scope: Inquire before buying




Global Anti-Obesity Drugs Market, by Region

• North America
• Europe
• South America
• MEA
• APAC
Global Anti-Obesity Drugs Market Key Players

• Boehringer Ingelheim GmbH
• Arena Pharmaceuticals Inc.
• Takeda Pharmaceuticals Company Limited
• Zydus Cadila
• Rhythm Pharmaceuticals
• Merck & Co. Inc.
• Eisai Co. Ltd.
• Novo Nordisk A/S
• Orexigen Therapeutics Inc.
• GlaxoSmithKline PLC
• F. Hoffmann-La Roche
• Shionogi Inc.
• Norgine B.V.
• Pfizer Inc.
• Zafgen



           

For a More Information Visit @:  https://www.maximizemarketresearch.com/market-report/global-anti-obesity-drugs-market/100768/

This Report Is Submitted By: Maximize Market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

                                                                                          

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.